LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod

Photo from wikipedia

Adult T-cell leukemia/lymphoma (ATL) is a non-Hodgkin lymphoma caused by the human T-lymphotropic virus type 1. The indolent variant manifests on the skin as pruritic papules and plaques. Current treatment… Click to show full abstract

Adult T-cell leukemia/lymphoma (ATL) is a non-Hodgkin lymphoma caused by the human T-lymphotropic virus type 1. The indolent variant manifests on the skin as pruritic papules and plaques. Current treatment regimens for cutaneous ATL include watchful waiting; skin directed therapy, such as radiation, topical steroids, or ultraviolet light; or the use of oral agents, including interferon-α or zidovudine. Multiagent chemotherapy, notably mogamulizumab, is used for aggressive variantes.1,2 Chemotherapeutic agents used in ATL can be costly and associated with significant adverse effects. Imiquimod is an immunomodulator approved for actinic keratosis, primary superficial basal cell carcinoma, and genital warts. Off-label use has been efficacious in mycosis fungoides, lentigo maligna melanoma, HIV-negative Kaposi sarcoma, and primary cutaneous anaplastic large-cell lymphoma.3, 4, 5 We present a patient in whom nearly complete resolution of ATL was achieved with topical imiquimod therapy.

Keywords: cell leukemia; cell; leukemia lymphoma; adult cell

Journal Title: JAAD Case Reports
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.